Dipip Capsules 40/320 Mg 2X8s
Brand : hilton pharma
How it works
Dihydroartemisinin has fastest action on malarial parasite among all artemisinin derivatives by rapidly eliminating blood schizonts and also have strong effect on early and late trophozoites. Dihydroartemisinin concentrates selectively into cells contracted by parasites and reacts with heam to kill the parasites. This reaction produces poisonous free radicals that can destroy membranes of parasites. Piperaquine, a derivative of 4-aminoquinoline group, have strong action on blood schizonts and late trophozoites. Piperaquine inhibits the heamozoin formation and interacts with the heam to form ferriprotoporphyrin-piperaquine complex (FP-Piperaquine complex) which is highly toxic and damage the membrane of all types of malarial parasites and destroy them effectively. Both Dihydroartemisinin and Piperaquine also have strong action on gametocytes which help to prevent the malaria transmission .
DIPIP CAP 40/320 MG 2X8'S
Dihydroartemisinin , Piperaquine Phosphate
Requires Prescription (YES/NO)
It is use as first line treatment for the uncomplicated P. falciparum malaria including multi-drug resistant strains. Dihydroartemisinin + Piperaquine Phosphate is also effective against P. vivax malaria and has strong action on gametocytes. Piperaquine is also used as prophylaxis due to the advantage of its longer half life .
Nausea, vomiting, stomach ache, diarrhea, headache, dizziness itching pruritus etc.
When not to Use
Patients with hypersensitivity to any of Artemisinin’s derivative and Piperaquine Phosphate component.
The recommended dose of Dihydroartemisinin is given 4mg/kg/day & Piperaquine Phosphate is given 32mg/kg/day ; >15 year : day 1 : 4 tab, day 2: 2 , tab 3 : 2 tab ; 11-14 year : day 1 : 3 tab , day 2 : 1½ tab , day 3 : 1½ tab ; 7-10 year : day 1 : 2 tab , day 2 : 1 tab , day 3 :1 tab ; 1-6 year : day 1 : 1 tab , day 2 : 1/2 tab , day 3 : 1/2 tab . OR As directed by your physician.
Storage yes or /no
Store this medicine at room temperature, away from direct light and heat.
Exposure to piperaquine may also be increased when co-administered with mild or moderate CYP3A4-inhibitors (e.g. oral contraceptives). Therefore, caution should be applied when co-administering Eurartesim with any CYP3A4-inhibitor and ECG monitoring should be considered.
The long half-life of piperaquine (about 22 days) should be kept in mind in the event that another anti-malarial agent is started due to treatment failure or a new malaria infection .
Piperaquine is a mild inhibitor of CYP3A4. Caution is recommended when co-administering with medicinal products exhibiting variable patterns of inhibition, induction or competition for CYP3A4 as the therapeutic and/or toxic effects of some co-administered medicinal products could be altered.
Piperaquine is also a substrate of CYP3A4. A moderate increase of piperaquine plasma concentrations (<2-fold) was observed when co-administered with strong CYP3A4 inhibitors, resulting in a potential exacerbation of the effect on QTc prolongation .
Always consult your physician before using any medicine.
Inhibitors , inducers and substrates of CYP3A4 , substrates of CYP2C19 , CYP2E1 and CYP1A2 , grapefruit juice , drugs that prolong QT interval.
syr bd 1cc insulin 6mm syringe 1s
disprin 300mg dispersible tablets 100s (pack size 10 x 10s)
panadol 500mg tablets 200s ( pack size 20x10s)